Adicet Bio, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Adicet Bio, Inc. (formerly Adicet Therapeutics, Inc.) on September 15, 2020. The filing reports a corporate rebranding, a reverse stock split, and the appointment of a new executive leadership team effective September 15, 2020.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. This report focuses exclusively on corporate governance changes and executive compensation structures.
Material Changes
- Stock Listing and Ticker: Following a reverse stock split, the Company's common stock began trading on The Nasdaq Global Market under the new ticker symbol "ACET" on September 16, 2020. The previous ticker "TORC" was retired. A new CUSIP number (007002108) was assigned.
- Executive Appointments: The Company appointed five new executive officers, including a new President and CEO, CFO, CMO, CHRO, and Chief Innovation Officer.
Management Commentary and Compensation Details
The filing details employment agreements for the new executive team, outlining base salaries, target bonuses, and change-in-control severance provisions:
- Chen Schor (President & CEO): Base salary of $520,000; target bonus of 50% of base. Severance includes 1.5x salary and bonus plus 18 months of health insurance upon qualifying termination.
- Carrie Krehlik (SVP & CHRO): Base salary of $300,000; target bonus of 40% of base. Severance includes 1x salary and bonus plus 12 months of health insurance.
- Francesco Galimi, M.D., Ph.D. (SVP & CMO): Base salary of $400,000; target bonus of 40% of base. Severance includes 1x salary and bonus plus 12 months of health insurance.
- Lloyd Klickstein, M.D., Ph.D. (Chief Innovation Officer): Base salary of $403,700; target bonus of 40% of base. Severance includes 1x salary and bonus plus 18 months of health insurance.
- Nick Harvey (CFO): Base salary of $385,000; target bonus of 40% of base. Received an inducement stock option for 195,898 shares. Severance includes 1x salary and bonus plus 12 months of health insurance.
All agreements are "at-will" and include standard indemnification and non-solicitation provisions.
Investor Verification Checklist
- Verify the trading status and share price of the new ticker symbol "ACET" on The Nasdaq Global Market.
- Confirm the impact of the reverse stock split on existing shareholdings and the new CUSIP number (007002108).
- Review the total potential cash and equity compensation obligations for the new executive team, particularly in the event of a change in control.
- Check for any subsequent filings regarding the Company's financial position, as this 8-K does not contain financial statements.